Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions

Fig. 1

Three classes of ADAS-cog trajectories (higher score is associated with lower cognitive function/greater decline) in participants from placebo or no treatment arms of clinical trials/studies. a Disease progression trajectories estimated by our latent class mixed model, where an increase in ADAS-cog scores (y axis) indicates worsening of cognitive function. bd Individual participant trajectories for each of the three resulting classes (each line represents a single participant). Bold lines represent a smoothing of the data; shaded areas represent the 0.95 confidence interval. ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale

Back to article page